Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(2):200–204. doi: 10.1111/j.1349-7006.2003.tb01419.x

Combination effect of AC‐7700, a novel combretastatin A‐4 derivative, and cisplatin against murine and human tumors in vivo

Yoshihiro Morinaga 1,✉, Yasuyo Suga 1, Sumiko Ehara 2, Katsuhiro Harada 2, Yukio Nihei 1, Manabu Suzuki 1
PMCID: PMC11160070  PMID: 12708497

Abstract

The in vivo combination effect of AC‐7700, a novel combretastatin A‐4 derivative, and cisplatin (CDDP) was examined. The combination of AC‐7700 and CDDP increased antitumor activity against murine colon 26 tumor in mice and cured the mice. This combination effect was found over wide dosage ranges of AC‐7700 (20–80 mg/kg) and CDDP (2.5–5 mg/kg). Moreover, this combination augmented antitumor activity against murine S180 and M109 tumors, and human LX‐1 and LS180 tumor xenografts in mice. The effect was the strongest when AC‐7700 and CDDP were administered simultaneously. To study this combination effect we measured the concentrations of CDDP in tumors, plasma and kidneys of the mice with colon 26 tumor. In the combination with AC‐7700, the concentration of CDDP in the tumors increased from 0.5 to 96 h after administration, but did not change or decrease in plasma or kidneys. Against human LS180 xenografts in mice, the combination similarly increased the concentration of CDDP in the tumors. These results suggest that AC‐7700 may specifically augment the accumulation of CDDP in tumors, and thus has the potential to be useful in combination chemotherapy with CDDP. (Cancer Sci 2003; 94: 200–204)

References

  • 1. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garia‐Randall D. Isolation and structure of the strong cell growth and tubulin inhibitor com‐bretastatin A4. Experientia 1989; 45: 205–11. [DOI] [PubMed] [Google Scholar]
  • 2. El‐Zayar AAE, Degen D, Drabek S, Clark GM, Pettit GR, von Hoff DD. In vitro evaluation of the antineoplastic activity of combretastatin A‐4, a natural product from Combretum caffrum. (arid shrub). Anticancer Drugs 1993; 4: 19–25. [DOI] [PubMed] [Google Scholar]
  • 3. Ohsumi K, Nakagawa R, Fukuda Y, Hatanaka T, Morinaga Y, Nihei Y, Ohishi K, Suga Y, Akiyama Y, Tsuji T. Novel combretastatin analogues effective against murine solid tumors: design and structure‐activity relation‐ships. J Med Chem 1998; 41: 3022–32. [DOI] [PubMed] [Google Scholar]
  • 4. Nihei Y, Suga Y, Morinaga Y, Ohishi K, Okano A, Ohsumi K, Hatanaka T, Nakagawa R, Tsuji T, Akiyama Y, Saito S, Hori K, Sato Y, Tsuruo T. A novel conbretastatin A‐4 derivative, AC‐7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn J Cancer Res 1999; 90: 1016–25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Hori K, Saito S, Nihei M, Suzuki M, Sato Y. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A‐4 derivative, AC‐7700. Jpn J Cancer Res 1999; 90: 1026–38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Nihei Y, Suzuki M, Okano A, Akiyama Y, Hori K, Saito S, Sato Y. Anti‐vascular effects of AC‐7700 on solid tumors; comparison with other tubulin binding agents. Proc Am Assoc Cancer Res 1998; 39: 167. [Google Scholar]
  • 7. Shinkai T, Saijo N, Tominaga K, Eguchi K, Shimizu E, Sasaki Y, Fujita J, Futami H. Comparison of vindesine plus cisplatin or vindesine plus mitomy‐cin in the treatment of advanced non‐small cell lung cancer. Cancer Treat Rep 1985; 69: 945–51. [PubMed] [Google Scholar]
  • 8. Johnson BE, Salem C, Nesbitt J. Limited stage small cell lung cancer treated with concurrent hyperfractionated chest radiotherapy and etoposide/ cisplatin. Lung Cancer 1993; 9: 215–65. [Google Scholar]
  • 9. Belinson JL, McClure M, Ashikaga T, Krakoff IH. Treatment of advanced and recurrent ovarian carcinoma with cyclophosphamide, doxorubicin, and cisplatin. Cancer 1984; 54: 1983–90. [DOI] [PubMed] [Google Scholar]
  • 10. Bonomi P, Kim K, Kusler J, Johnson D. Cisplatin/etoposide vs paclitaxel/ cisplatin/G‐CSF vs paclitaxel/cisplatin in non‐small‐cell lung cancer. Oncology (Huntingt) 1997; 11: 9–10. [PubMed] [Google Scholar]
  • 11. Wozniak AJ, Crowly JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor, SA , Gandara DR, Livingston RB. J Clin Oncol 1998; 16: 2459–65. [DOI] [PubMed] [Google Scholar]
  • 12. Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Nakagawa K, Hirashima T, Tamanoi M, Nitta T, Yana T. Phase I study of irinotecan and cisplatin with granulocyte colony‐stimulating factor support for advanced non‐small‐cell lung cancer. J Clin Oncol 1994; 12: 90–6. [DOI] [PubMed] [Google Scholar]
  • 13. Wood SA, Vlassopoulos D, Mucci A. Effects of concentrated matrices on the determination of traces of platinum and gold in aqueous samples using solvent extraction‐Zeeman effect graphite furnace atomic absorption spectrome‐try and inductively coupled plasma‐mass spectrometry. Anal Chim Acta 1990; 229: 227–38. [Google Scholar]
  • 14. Himes RH, Kersey RN, Heller‐Bettinger I, Samson FE. Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on micro‐tubules in vitro . Cancer Res 1976; 36: 3798–802. [PubMed] [Google Scholar]
  • 15. Lee K, Tanaka M, Kanamaru H, Hashimura T, Yamamoto I, Konishi J, Kuse F. In vitro antagonism between cisplatin and vinca alkaloids. Br J Cancer 1989; 59: 36–41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloid: anti‐vascular effects in a murine tumour. Eur J Cancer 1993; 29A: 1320–4. [DOI] [PubMed] [Google Scholar]
  • 17. Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Antivascular approaches to solid tumor therapy: evaluation of tubulin binding agents. Br. J. Cancer 1996; 74 Suppl 27: S86–S88. [PMC free article] [PubMed] [Google Scholar]
  • 18. Ozawa S, Sugiyama Y, Mitsuhashi Y, Kobayashi T, Inaba M. Cell killing action of cell cycle phase‐non‐specific antitumor agents is dependent on concentration‐time product. Cancer Chemother Pharmacol 1988; 21: 185–90. [DOI] [PubMed] [Google Scholar]
  • 19. Chaplin DJ, Pettit GR, Hill SA. Anti‐vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999; 19: 189–96. [PubMed] [Google Scholar]
  • 20. Li L, Rojiani AM, Siemann DW. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A‐4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncol 2002; 41: 91–7. [DOI] [PubMed] [Google Scholar]
  • 21. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002; 99: 1–6. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES